The bill S. 5383 proposes to classify two substances, MGM-15 and MGM-16, as Schedule I controlled substances under the Controlled Substances Act. Additionally, it seeks to categorize synthetic 7-hydroxymitragynine and Mitragynine Pseudoindoxyl as Schedule I controlled substances as well. This classification indicates that these substances are considered to have a high potential for abuse and no accepted medical use.
Supporters of the bill argue that scheduling these substances is necessary to protect public health and safety. They highlight concerns about the potential for abuse and addiction associated with synthetic derivatives of kratom and other related substances, emphasizing the need for regulatory oversight.
Critics of the bill contend that scheduling these substances could hinder research and limit access to potential therapeutic benefits. They argue that the decision is driven by fear rather than scientific evidence, and express concerns about the implications for individuals who use these substances for pain management or other health issues.
The bill S. 5383 aims to amend the Controlled Substances Act to schedule certain substances, including MGM-15, MGM-16, and synthetic 7-hydroxymitragynine. The sponsor, Bernie Moreno, has received significant contributions from the health professionals sector, totaling $360 million. However, there is no direct overlap between the interests of these donors and the subject matter of the bill. The health professionals' contributions do not indicate a vested interest in the scheduling of these specific substances, which suggests that the potential for conflict of interest is minimal. Additionally, the retired sector, contributing $112.5 million, does not appear to have any relevant ties to the bill's content either. Therefore, while large sums are involved, the lack of direct industry overlap results in a low risk assessment for conflicts of interest.
Top industries funding Bernie Moreno, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
